Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) has indicated that it has got positive data from ENABLE-1, the first of two Phase III studies evaluating Promacta (eltrombopag) in patients suffering from hepatitis C-related thrombocytopenia.
Subscribe to our email newsletter
The US Food and Drug Administration has approved eltrombopag under the trade name Promacta as a treatment of chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins or surgical removal of the spleen, in November 2008.
Eltrombopag has got authorization for use in EU, along with Ireland, India, Bahrain, Chile, Russia, Japan, Turkey, Taiwan, Kuwait, Singapore and Australia, under the trade name Revolade.